These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22310913)

  • 1. Second malignancies after multiple myeloma: from 1960s to 2010s.
    Thomas A; Mailankody S; Korde N; Kristinsson SY; Turesson I; Landgren O
    Blood; 2012 Mar; 119(12):2731-7. PubMed ID: 22310913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
    Mailankody S; Pfeiffer RM; Kristinsson SY; Korde N; Bjorkholm M; Goldin LR; Turesson I; Landgren O
    Blood; 2011 Oct; 118(15):4086-92. PubMed ID: 21795746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
    Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
    Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
    Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.
    Castillo JJ; Gertz MA
    Leuk Lymphoma; 2017 Apr; 58(4):773-780. PubMed ID: 27546465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
    Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.
    Goldin LR; Kristinsson SY; Liang XS; Derolf AR; Landgren O; Björkholm M
    J Clin Oncol; 2012 Jan; 30(2):179-83. PubMed ID: 22162584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Yamasaki S; Suzuki R; Hatano K; Fukushima K; Iida H; Morishima S; Suehiro Y; Fukuda T; Uchida N; Uchiyama H; Ikeda H; Yokota A; Tsukasaki K; Yamaguchi H; Kuroda J; Nakamae H; Adachi Y; Matsuoka KI; Nakamura Y; Atsuta Y; Suzumiya J
    Bone Marrow Transplant; 2017 Jul; 52(7):969-976. PubMed ID: 28368379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.
    Boquoi A; Banahan SM; Mohring A; Savickaite I; Strapatsas J; Hildebrandt B; Kobbe G; Gattermann N; Haas R; Schroeder T; Germing U; Fenk R
    Ann Hematol; 2022 May; 101(5):1031-1038. PubMed ID: 35262868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
    Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
    Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related myelodysplasia and acute myeloid leukemia.
    Bhatia S
    Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
    Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
    Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?
    Dasanu CA; Mewawalla P; Grabska J
    Curr Med Res Opin; 2012 Jul; 28(7):1129-40. PubMed ID: 22533678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma.
    DeStefano CB; Gibson SJ; Sperling AS; Richardson PG; Ghobrial I; Mo CC
    Semin Oncol; 2022 Feb; 49(1):19-26. PubMed ID: 35105451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
    Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia].
    Hamano A; Shingaki S; Abe Y; Miyazaki K; Sekine R; Nakagawa Y; Tsukada N; Hattori Y; Suzuki K
    Rinsho Ketsueki; 2014 Apr; 55(4):428-35. PubMed ID: 24850453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.